JAM
BCRX icon

Jupiter Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jupiter Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Buy
1,642,874
+446,503
+37% +$4.04M 0.08% 254
2026
Q1 		$11.4M Sell
1,196,371
-1,248
-0.1% -$9.69K 0.06% 267
2025
Q4 		$9.34M Sell
1,197,619
-858,296
-42% -$6.2M 0.07% 221
2025
Q3 		$15.6M Sell
2,055,915
-22,051
-1% -$184K 0.13% 179
2025
Q2 		$18.6M Sell
2,077,966
-71,003
-3% -$661K 0.16% 172
2025
Q1 		$16.1M Buy
2,148,969
+971,040
+82% +$7.83M 0.15% 183
2024
Q4 		$8.86M Buy
1,177,929
+108,030
+10% +$820K 0.09% 236
2024
Q3 		$8.13M Buy
+1,069,899
New +$8.13M 0.07% 242
2022
Q1 		– Sell
-62,704
Closed -$864K – 514
2021
Q4 		$864K Buy
+62,704
New +$830K 0.01% 424

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Asset Management's BCRX Position: Q2 2026 in Review

Jupiter Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 37% in Q2 2026, buying an estimated $4.04M and bringing the position to 1,642,874 shares worth $16.4M. The position accounts for 0.08% of the portfolio, ranked #254.

Jupiter Asset Management first reported a position in BCRX in Q4 2021 and has held it in 9 quarters since. The position peaked at $18.6M in Q2 2025. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Jupiter Asset Management held 1,642,874 shares of BioCryst Pharmaceuticals worth $16.4M as of Q2 2026.
  • Jupiter Asset Management bought 446,503 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $4.04M.
  • BioCryst Pharmaceuticals made up 0.08% of Jupiter Asset Management's portfolio in Q2 2026, its #254 holding.
  • Jupiter Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
  • Jupiter Asset Management's BioCryst Pharmaceuticals position peaked at $18.6M in Q2 2025.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.